AAPG Ascentage Pharma Group Internat
$14.85▼ -0.90%
Healthcare
Other
Volume 8.9K
Avg Volume (10D) 8.0K
Key Metrics & Fundamentals
Market Cap
$1.39B
P/E Ratio
–
Div Yield
0.00%
52W Range
14.46 - 34.50
% vs 50 MA
-6.26%
% vs 200 MA
-26.11%
RSI-14
46.0
MACD Histogram
+0.0400
Beta (1Y vs SPY)
1.25
Gross Rev
–
Gross Profit
–
EBITDA
–
COGS
–
Operating Exp
–
Operating Income
–
EBIT
–
Pretax Income
–
Net Income
–
Price & Volume History
Loading chart…
Recent News
William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage
Business Wire · Oct 21, 2026 12:30 PM ET
Ascentage Pharma's Lisaftoclax Granted China Breakthrough Designation
MT Newswires · Oct 21, 2026 5:49 AM ET
Ascentage Pharma’s Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL
GlobeNewswire · Oct 20, 2026 7:30 PM ET
Ascentage Pharma (SEHK:6855) Stock Looks Above Fair Value After The Fall
Simply Wall St. · Oct 19, 2026 3:14 PM ET
3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
MarketBeat · Oct 10, 2026 10:35 AM ET
3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight
MarketBeat · Oct 5, 2026 10:55 AM ET
Ascentage Pharma to Participate in Four Upcoming Investor Conferences
GlobeNewswire · Sep 2, 2026 8:00 AM ET
Ascentage Pharma Group International (SEHK:6855) Could Be 18% Undervalued After Half Year Losses
Simply Wall St. · Aug 28, 2026 1:07 AM ET
ASCENTAGE PHARMA GROUP INTERNATIONAL Q2 2026 Earnings Call Summary
Moby · Aug 21, 2026 8:30 AM ET
Ascentage Pharma Group International H1 Earnings Call Highlights
MarketBeat · Aug 20, 2026 11:04 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.